📣 ESMO Living Guidelines on Metastatic Colorectal Cancer v1.3: Updated recommendations and algorithms for the treatment of patient with BRAF-mut. 🔗 ow.ly/Vvst50WpHFh #ESMOGuidelines Chiara Cremolini erika martinelli Andres Cervantes ESMO - Eur. Oncology

RWE about @TNT in LARC 🧐N=1585 pts. Treatments: PRODIGE-23like: 18%, RÁPIDOlike: 33%, OPRAinduction 12%, OPRAconsolidation 16%. W&W: 12%, pCR/cCR: 23%, local failure: 8%, distant progression:16%. 5yOS 79% JAMA Oncology Juan OConnor Instituto Nacional de Cancerología EORTC 👏🏻👏🏻👏🏻

Necesitamos tiempo, lecturas y un lugar así.

Very pleased to be part of this important discussion on young onset GICancer at #ESMOGI25. Let's raise awareness!

85,500 personas… ÚNICO en Argentina, en Sud América, en toda América… el mas popular del mundo.

Falta muy poco!! Nuestra 1ra reunión de equipo cooperativo argentino @EMOGI ⁦Asociación Argentina de Oncología Clínica (AAOC)⁩ no se lo pierdan!!! 😊

Exciting science and clinical efficacy in this MD Anderson Cancer Center team science study led by Van Morris, MD In Cancer Cell. Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm cell.com/cancer-cell/fu…

💊 Oxaliplatin retreatment in refractory mCRC 🔗 doi.org/10.1016/j.esmo… 👥 102 pts (VH 3L/4L) 📊 PFS 4.0 mo | ORR 12% | DCR 39% ⭐ 27% best-responders ✅ Favorable: prior response, planned stop, ≥22 mo ox-free interval 🧬 No genomic predictors

Importante la concientizacion sobre cáncer digestivo a edad temprana. Por eso esto se va a discutir en el 1er Congreso en Punta del Este sobre esta problemática en LATAM 10 y 11 sept 2025 instagram.com/reel/DODzpUAiW…

PROMETCO: RW treatment patterns across the mCRC continuum (n=738). Guideline-concordant exposure. Median OS 36.4 mo from dx; 6.6 mo from 3L start. PFS fell 1L→3L, then stable to 6L. Survival aligned with long-term trial data. #mCRC #OncoTwitter #RWE authors.elsevier.com/sd/article/S29…

📊 PROMETCO (real-world mCRC, n=738, 18 countries) 🔗 doi.org/10.1016/j.esmo… 💊 FP 99% | IRI 96% | OX 88% | anti-VEGF 79% | anti-EGFR 40% 📉 OS: 36.4 mo (dx) | 6.6 mo (3L) ⏳ PFS: 1L 9.2 mo → 3L 2.7 mo → stable (~2.3 to 6L) 🧬 OS by mut: RAS 32.7 | BRAF 26.8 | WT 40.6 mo

🎯Congreso Argentino e Internacional de oncologia Clínica #urooncologia #urooncolatam Maite Bourlon Javier Puente #IgnacioDuran #GustavoSanchezTurati

We hope this first publication will help other institutions address the needs of our #earlyonset #Cancer patients. 🙏🏻💪

🧬📊 New study in @JHEPReports 🔍 Young-onset biliary tract cancer: ✅ Better survival ✅ More FGFR2 fusions ✅ Greater benefit from matched targeted therapies 🤝 Collaborative work between 🇫🇷 France & 🇪🇸 Spain 📖 doi.org/10.1016/j.jhep… #BTC #Oncology #PrecisionMedicine #FGFR2

💡 Pancreatic cancer’s big question: Which neoadjuvant is best? PREOPANC-2 says… both. 👥 Population • 369 pts | Resectable / borderline PDAC • Phase III | 19 Dutch centers 🧪 Arms 1️⃣ FOLFIRINOX (8 cycles) ➡️ Surgery (no adjuvant) 2️⃣ Gemcitabine-CRT (3 cycles + RT) ➡️

Lerning about the sweet Kiss of immunotherapy in #Cancer with Gabriel Rabinovich and team FLoscoMD Juan Pablo Sade Juan OConnor andrés ornelas Federico Esteso Dr. Tomás Soulé Instituto Alexander Fleming Fundación Cáncer

👏 to MD Anderson Cancer Center -led effort reporting out biomarkers for response to PD1 +/- CTLA4 in MSI-H CRC! Unfortunately not all pts experience benefit, and studies like these directing us on who may vs may not benefit will help identify paths towards future improvements for even

Teresa Amaral, MD, PhD; Evandro de Azambuja, MD, PhD; Angela Lamarca; Jon Lim, MRCP PhD